Ceribell is the developer of a highly innovative electroencephalography (EEG) device, designed to make the diagnosis of neurological patients drastically more efficient.
Ceribell, Inc. announced today it has closed a $50 million financing round led by new investor Ally Bridge Group, with participation from existing shareholders. The financing was structured as an extension of the company's previously announced Series C financing.
